Antibiotics and Proton Pump Inhibitors Suppress the Efficacy of Immunotherapy Against Non-small Cell Lung Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2020 May 7

PMID 32374445

Citations 7

Authors

Xiayao Diao

Affiliations

Soon will be listed here.

Citing Articles

Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis.

Zhao Z, Yua Y Technol Health Care. 2024; 32(6):4515-4536.

PMID: 39520156 PMC: 11612965. DOI: 10.3233/THC-240660.

Concomitant Medications Alter Clinical Outcomes in Patients with Advanced Digestive Tract Cancer Receiving PD-1 Checkpoint Inhibitors Combined with Antiangiogenetic Agents.

Wang Y, Wu Z, Zhu X, Zheng Y, Yang Y, Tu J J Gastrointest Cancer. 2024; 55(3):1388-1400.

PMID: 39080229 DOI: 10.1007/s12029-024-01095-7.

Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials.

Almansour S, Alqudah M, Abuhelwa Z, Al-Shamsi H, Semreen M, Bustanji Y Sci Rep. 2024; 14(1):591.

PMID: 38182614 PMC: 10770405. DOI: 10.1038/s41598-023-48640-1.

The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Hu D, Wong W, Zhou J, Luo J, Cai S, Zhou H J Oncol. 2022; 2022:1001796.

PMID: 35855807 PMC: 9288308. DOI: 10.1155/2022/1001796.

Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.

Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A Cancers (Basel). 2022; 14(6).

PMID: 35326555 PMC: 8945985. DOI: 10.3390/cancers14061404.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R . Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018; 97(33):e11936. PMC: 6113026. DOI: 10.1097/MD.0000000000011936. View

Rossi J, Ceballos P, Lu Z . Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond). 2019; 39(1):34. PMC: 6567551. DOI: 10.1186/s40880-019-0379-3. View

Consonni D, Mensi C . Comment on the paper 'Boffetta et al. Validation of the diagnosis of mesothelioma and BAP1 protein expression in a cohort of asbestos textile workers from Northern Italy. Ann Oncol 2018; 29(2): 484-489'. Ann Oncol. 2018; 30(2):340-341. DOI: 10.1093/annonc/mdy521. View

Imhann F, Bonder M, Vich Vila A, Fu J, Mujagic Z, Vork L . Proton pump inhibitors affect the gut microbiome. Gut. 2015; 65(5):740-8. PMC: 4853569. DOI: 10.1136/gutjnl-2015-310376. View

Yan L, Zhang W . Precision medicine becomes reality-tumor type-agnostic therapy. Cancer Commun (Lond). 2018; 38(1):6. PMC: 5953403. DOI: 10.1186/s40880-018-0274-3. View

Feng R, Zong Y, Cao S, Xu R . Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond). 2019; 39(1):22. PMC: 6487510. DOI: 10.1186/s40880-019-0368-6. View

Gopalakrishnan V, Helmink B, Spencer C, Reuben A, Wargo J . The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 2018; 33(4):570-580. PMC: 6529202. DOI: 10.1016/j.ccell.2018.03.015. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

10.

Herbst R, Morgensztern D, Boshoff C . The biology and management of non-small cell lung cancer. Nature. 2018; 553(7689):446-454. DOI: 10.1038/nature25183. View

11.

Assi H, Kamphorst A, Moukalled N, Ramalingam S . Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2017; 124(2):248-261. DOI: 10.1002/cncr.31105. View

12.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

13.

Chalabi M, Cardona A, Nagarkar D, Dhawahir Scala A, Gandara D, Rittmeyer A . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020; 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. View

14.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

15.

Larsen T, Hussmann D, Nielsen A . PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer. Cancer Commun (Lond). 2019; 39(1):30. PMC: 6545701. DOI: 10.1186/s40880-019-0376-6. View

16.

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View